Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase
II
study
Authors
Keywords
-
Journal
Thoracic Cancer
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-28
DOI
10.1111/1759-7714.13490
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)
- (2019) Morihito Okada et al. CLINICAL CANCER RESEARCH
- Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
- (2019) Hirokazu Taniguchi et al. Thoracic Cancer
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies
- (2019) Jessica A. Hellyer et al. LUNG CANCER
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) P. Baas et al. ANNALS OF ONCOLOGY
- Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial)
- (2015) Seiki Hasegawa et al. International Journal of Clinical Oncology
- Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
- (2010) David S. Ettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients☆
- (2008) Piero Borasio et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma
- (2008) Jacek Jassem et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
- (2008) Justin Stebbing et al. LUNG CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started